Oregon Health & Science University

Site:	Oregon Health & Science University
Address:
City:	Portland
State:	OR
Zip:	97239
Country:	USA

17 trials at this site

Phase	Trial [desc]	Trial Status	Site Status	Drug	NCT#
			Active
2	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT06208748
1/2	Phase I/II Study of PDR001 in Patients With Advanced Malignancies	Active, not recruiting	Closed	PDR001	NCT02404441
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Active, not recruiting	Closed	INBRX-109 + Temozolomide	NCT03715933
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	DS-6157a	NCT04276415
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Recruiting	Active	Ziftomenib + Imatinib	NCT06655246
1	A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit	Recruiting	Active	NN3201	NCT06805825
1	A Study of NB003 in Patients With Advanced Malignancies	Active, not recruiting	Active	NB003	NCT04936178
1/2	A Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
1	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT02571036
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
1	A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients	Completed	Active	Imatinib + BYL719	NCT01735968
1/2	[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)	Active, not recruiting	Closed	neoBOMB1	NCT03872778